YMC 5 Year Vision
YMC’s Corporate Vision was recently articulated by YMC President Ryuji Yamamura, and published in an issue of Newsweek International.
In the article, Mr. Yamamura points out that, “… the greatest strength of YMC’s business model is that we are uniquely positioned to offer our customers a platform that allows them to determine which packing materials, which devices/system/instruments, and which methods can be applied to achieve maximum production efficiency.”
The article can be found here.
Previous Article
Large scale production of peptide program announced Related Posts
September 4, 2026
YMC America Brings U.S.-Supplied ASME U-Stamped DAC Columns to Pharmaceutical Manufacturers
YMC America will be the First U.S.-Based Supplier of ASME U-Stamped DAC Columns.
The company’s DAC columns support pharmaceutical and biopharmaceutical customers from process development through commercial production. Systems are used in laboratory, pilot, and production-scale chromatography applications, including purification processes for peptides, oligonucleotides, and small-molecule APIs.
September 10, 2026
Analytical Technologies for Therapeutic Peptides
Therapeutic peptides are an emerging class of active pharmaceutical ingredients that, together with other classes of bioproducts, have been attracting considerable attention due to their unique advantages. Their structure is based on well-defined amino acid sequences that may or may not contain structural modifications, resulting in molecules that generally range from 500 to 5000 Da. Currently, many examples can be used as medicines related to hormones, growth factors, neurotransmitters, among others.
September 9, 2026
Tecnologias Analíticas para Peptídeos Terapêuticos- Portuguese
Os peptídeos terapêuticos são uma classe emergente de insumos farmacêuticos ativos que, juntamente com outras classes de bioprodutos, vêm despertando grande interesse devido às suas vantagens únicas.
